Katherine Fuh

Medicine & Life Sciences

1. Ovarian Neoplasms 100%
2. Endometrial Neoplasms 64%
3. Neoplasms 37%
4. Survival 34%
5. Uterine Neoplasms 33%
6. Heterografts 30%
7. Neoplasm Metastasis 25%
8. Receptor Protein-Tyrosine Kinases 20%
9. Platinum 20%
10. Paclitaxel 19%
11. Cancer Survivors 19%
12. Ovarian Epithelial Carcinoma 18%
13. Homologous Recombination 17%
14. Drug Therapy 17%
15. Radiotherapy 16%
16. Cardiogenic Shock 16%
17. Poly(ADP-ribose) Polymerase Inhibitors 15%
18. Hemodynamics 15%
19. Randomized Controlled Trials 15%
20. Text Messaging 15%
21. Vasoconstriction 14%
22. Shock 14%
23. Weight Loss 14%
24. Mesenteric Ischemia 13%
25. Therapeutics 13%
26. Obesity 12%
27. Bevacizumab 11%
28. Renal Cell Carcinoma 11%
29. Recurrence 10%
30. Radiation 10%
31. olaparib 10%
32. Hemorrhagic Shock 10%
33. Angiotensins 10%
34. R428 compound 10%
35. Discoidin Domain Receptor 2 10%
36. Recombinational DNA Repair 9%
37. Tumor Burden 9%
38. Proteogenomics 9%
39. entinostat 9%
40. Lymph Node Excision 9%
41. Renin 9%
42. liposomal doxorubicin 9%
43. isosorbide-5-mononitrate 8%
44. taxane 8%
45. DNA Repair-Deficiency Disorders 8%
46. Percutaneous Nephrostomy 8%
47. Weights and Measures 8%
48. Oncologists 8%
49. Paracrine Communication 8%
50. Vulvar Neoplasms 8%